Reuters logo
BRIEF-Cempra’s fusidic acid achieves primary endpoint in phase 3 study of Absssi
February 24, 2017 / 12:15 PM / 10 months ago

BRIEF-Cempra’s fusidic acid achieves primary endpoint in phase 3 study of Absssi

Feb 24 (Reuters) - Cempra Inc

* Cempra’s fusidic acid achieves primary endpoint in phase 3 study of Absssi

* Fusidic acid met primary endpoint and secondary efficacy endpoints

* Fusidic acid well tolerated in study

* “Look forward to meeting with fda to discuss next steps required to bring fusidic acid to patients in United States” Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below